Novo Nordisk A/S (NVO)
82.75
-0.88 -1.05%
NYSE
Jun 17, 16:59
USD
Novo Nordisk PE Ratio:
28.64 for June 17, 2021View 4,000+ financial data types
Browse...
View Full Chart
PE Ratio Chart
Export Data
Save Image
Print Image
For advanced charting, view our full-featured
Fundamental Chart
Historical PE Ratio Data
View and export this data going back to 1992.
Start your Free Trial
Export Data
Date Range:
| Data for this Date Range | |
|---|---|
| June 17, 2021 | 28.64 |
| June 16, 2021 | 28.95 |
| June 15, 2021 | 29.27 |
| June 14, 2021 | 29.22 |
| June 11, 2021 | 29.23 |
| June 10, 2021 | 29.34 |
| June 9, 2021 | 28.90 |
| June 8, 2021 | 28.48 |
| June 7, 2021 | 28.10 |
| June 4, 2021 | 28.02 |
| June 3, 2021 | 27.58 |
| June 2, 2021 | 27.29 |
| June 1, 2021 | 27.41 |
| May 28, 2021 | 27.31 |
| May 27, 2021 | 27.28 |
| May 26, 2021 | 27.81 |
| May 25, 2021 | 27.82 |
| May 24, 2021 | 28.28 |
| May 21, 2021 | 28.14 |
| May 20, 2021 | 27.98 |
| May 19, 2021 | 27.71 |
| May 18, 2021 | 27.56 |
| May 17, 2021 | 27.89 |
| May 14, 2021 | 27.38 |
| May 13, 2021 | 27.31 |
| May 12, 2021 | 27.01 |
| May 11, 2021 | 26.52 |
| May 10, 2021 | 26.40 |
| May 7, 2021 | 26.19 |
| May 6, 2021 | 25.68 |
| May 5, 2021 | 25.64 |
| May 4, 2021 | 25.66 |
| May 3, 2021 | 26.08 |
| April 30, 2021 | 25.60 |
| April 29, 2021 | 25.70 |
| April 28, 2021 | 25.65 |
| April 27, 2021 | 25.50 |
| April 26, 2021 | 25.65 |
| April 23, 2021 | 25.63 |
| April 22, 2021 | 25.66 |
| April 21, 2021 | 25.69 |
| April 20, 2021 | 25.36 |
| April 19, 2021 | 25.16 |
| April 16, 2021 | 24.98 |
| April 15, 2021 | 24.75 |
| April 14, 2021 | 24.42 |
| April 13, 2021 | 24.49 |
| April 12, 2021 | 24.04 |
| April 9, 2021 | 24.27 |
| April 8, 2021 | 23.97 |
| April 7, 2021 | 23.50 |
There is no data for the selected date range.
An error occurred. Please try again by refreshing your browser or contact us with details of your problem.
Advertisement
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS (ttm). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Benchmarks
| Genmab A/S | 33.66 |
| Forward Pharma A/S | -- |
| Ascendis Pharma A/S | -- |
PE Ratio Range, Past 5 Years
| Minimum | 14.36 | Nov 23 2016 |
| Maximum | 29.34 | Jun 10 2021 |
| Average | 21.52 |
PE Ratio Related Metrics
| PS Ratio | 9.681 |
| PEG Ratio | 2.079 |
| Price to Book Value | 20.61 |
| Price to Free Cash Flow | 39.08 |
| Price | 82.75 |
| Earnings Yield | 3.49% |
| Market Cap | 190.06B |
| PEGY Ratio | 1.848 |
| Operating PE Ratio | 23.30 |
| Normalized PE Ratio | 28.64 |
News
Amalgam, Novo Nordisk to Launch Dose Check Insulin Titration App in Europe, Asia
MT Newswires 06/16 14:51 ET
MT Newswires 06/16 14:51 ET
Novo Nordisk in pact for global expansion of Amalgam’s insulin titration app
SA Breaking News 06/16 10:04 ET
SA Breaking News 06/16 10:04 ET
UPDATE 1-Risk of patient overlap between Wegovy and Saxenda obesity drugs, Novo says
Yahoo 06/07 04:32 ET
Yahoo 06/07 04:32 ET
FDA approves Novo Nordisk’s obesity drug Wegovy, which helped people cut weight 15%
Yahoo 06/04 16:36 ET
Yahoo 06/04 16:36 ET
Advertisement
